Company
Utility Therapeutics
- Status
- Acquiredas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Utility therapeutics was an AMR Action Fund portfolio company that in April 2024 obtained U.S. FDA approval for pivmecillinam for the treatment of urinary tract infections (UTIs). It marked the first time in 20 years that the FDA approved a new treatment for UTIs. In July 2025, Alembic Pharmaceuticals acquired Utility.
About the company
- Status notes
- In July 2025, Alembic Pharmaceuticals acquired Utility.
Exit
- Acquisition
- 2025-07
Loading relationship preview